We are a novel biopharmaceutical development company dedicated to true global open innovation. We have set the ambitious goal of entering developed markets with a differentiated new drug development strategy, utilizing new biopharmaceutical substance patents. Today, all our employees strive to spread the seeds of hope for a healthy life for humankind.
Our core platform is the recombinant stabilized protein sGal-9 (stabilized Galectin-9). sGal-9 possesses long-term stability and enhanced activity compared to natural Galectin-9, and it has a customized mechanism for autoimmune diseases (inhibiting synovial fibroblast (FLS) proliferation and migration in RA, and inhibiting pDC and B cell activity in Lupus).
The differentiating factors of sGal-9 compared to global competitors include a new target (synovial fibroblasts) and a dual mechanism of action, allowing for the possibility of fundamental treatment and proactive responses to unmet medical needs.

GB910: A rheumatoid arthritis therapeutic targeting FLS (synovial fibroblasts).
GB930: A lupus therapeutic simultaneously targeting pDC and B cells.
GB100: A next-generation obesity therapeutic capable of inducing fat reduction while preventing muscle loss.